American Society of Anesthesiologists (ASA) physical status system predicts the risk of postoperative Clavien-Dindo complications greater than one at 90 days after robot-assisted radical prostatectomy: final results of a tertiary referral center.

Journal: Journal of robotic surgery
PMID:

Abstract

To test the hypothesis of an association between the American Society of Anesthesiologists (ASA) physical status classification system and the risk of 90-days postoperative complications after robot-assisted radical prostatectomy (RARP), graded using the Clavien-Dindo classification system (CDS). In a period ranging from January 2013 to October 2020, 1143 patients were evaluated. ASA classification was computed by trained anesthesiologists. Postoperative complications at 90 days after RARP were grouped as greater than one (CDS between 2 and 4a) versus up to one (CDS between 0 and 1). The risk association was computed using logistic regression models. According to ASA physical status classification system, patients were distributed as follows: 102 (8.9%) ASA 1, 934 (81.7%) ASA 2, and 107 (9.4%) ASA 3. Overall, 90-days postoperative complications occurred in 277 (24.2%) cases, of which 137 (12%) were graded as CDS 1 vs. 105 (9.2%) CDS 2 vs. 17 (1.5%) CDS 3a vs. 15 (1.3%) CDS 3b vs. 3 (0.3%) CDS 4a. ASA 2 and 3 patient categories were more likely to have 90-days postoperative complications CDS > 1 (12.5% and 16.8%, respectively) compared to ASA 1 patients (4.9%). The risk association was stronger for ASA 3 (odds ratio, [OR]: 4.085; 95%CI: 1.457-11.455; p = 0.007) than for ASA 2 (OR: 2.907; 95%CI: 1.106-7.285; p = 0.023) patient categories. After adjustment for clinical, pathological, and perioperative covariates, including pelvic lymph node dissection (performed vs. not performed), either ASA 2 or 3 categories remained independent predictors of 90-days postoperative complications CDS > 1. The risk of 90-days postoperative complications CDS > 1 after RARP increased as the ASA physical status deteriorated independently by performing or not an extended pelvic lymph node dissection. In the ASA 3 patients category, RARP should be performed at tertiary referral centers to safely manage the risk of postoperative complications.

Authors

  • Antonio Benito Porcaro
    Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy. drporcaro@yahoo.com.
  • Riccardo Rizzetto
    Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.
  • Alberto Bianchi
    Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.
  • Sebastian Gallina
    Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.
  • Emanuele Serafin
    Department of Urology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Piazzale Stefani 1, 37126, Verona, Italy.
  • Andrea Panunzio
    Department of Urology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Piazzale Stefani 1, 37126, Verona, Italy.
  • Alessandro Tafuri
    Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
  • Clara Cerrato
    Department of Urology, Azienda Ospedaliera Universitaria Integrata Verona, University of Verona, Piazzale Stefani 1, 37126, Verona, Italy.
  • Filippo Migliorini
    Department of Orthopaedic, Trauma, and Reconstructive Surgery, RWTH University Medical Centre, Aachen, Germany.
  • Stefano Zecchini Antoniolli
    Department of Urology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Piazzale Stefani 1, 37126, Verona, Italy.
  • Giovanni Novella
    Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
  • Vincenzo De Marco
    Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
  • Matteo Brunelli
    Department of Pathology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
  • Salvatore Siracusano
    Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
  • Maria Angela Cerruto
    Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.
  • Enrico Polati
    Department of Anesthesiology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Verona, Italy.
  • Alessandro Antonelli
    Department of Urology, Azienda Ospedaliera Universitaria Integrata Verona, University of Verona, Verona, Italy.